It's been hailed as a miracle cure for hepatitis C – but comes with a billion-dollar price tag.
The Commonwealth government is under pressure to subsidise Sovaldi, produced by drug company Gilead, that has been approved by the Therapeutic Goods Administration but has been rejected for listing on the Pharmaceutical Benefits Scheme on value-for-money grounds.
The Pharmaceutical Benefits Advisory Committee, the independent expert body that decides which drugs should be subsidised, will consider a second application to list the drug at its March meeting, along with applications to list three other new hepatitis treatments.
Read more...
No comments:
Post a Comment